Harvard Bioscience, Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing is an annual report, not a standalone quarterly filing; selected fourth-quarter figures are included below. Harvard Bioscience develops, manufactures and sells life-science research instruments, systems and laboratory consumables across more than 100 countries. Its product families are Cell and Animal Physiology, Lab Products and Services, and Molecular Separation and Analysis.
Financial performance and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | $104.5 million | $108.7 million |
| Gross profit / margin | $48.4 million / 46.3% | $48.7 million / 44.8% |
| Operating loss | $3.0 million | $1.7 million |
| Net loss | $4.3 million | $19.0 million |
| Operating cash flow | $5.4 million | $0.7 million |
| Cash and cash equivalents, year-end | $5.6 million | $6.7 million |
| Working capital, year-end | $30.9 million | $31.2 million |
| Debt, net of deferred financing costs | $13.7 million | $18.7 million |
Revenue fell 3.8% year over year, including an estimated 2.0% decline excluding foreign-exchange effects. Management attributed the decrease to currency translation, softer European research funding, slower-than-expected NIH funding and lower AHN revenue after its sale. Gross margin improved as facility consolidation savings took effect. Operating loss widened despite lower research and development and selling expenses, with higher general and administrative costs and AHN-related charges contributing. The lower net loss mainly reflects the prior-year $16.4 million increase in the U.S. deferred-tax valuation allowance; it does not indicate a return to profitability.
Fourth-quarter 2016 revenue was $26.4 million, compared with $28.4 million in fourth-quarter 2015. Fourth-quarter operating loss was $1.1 million and net loss was $1.3 million; fourth-quarter 2015 net loss was $17.1 million, including a substantial tax charge.
Cash, debt and capital resources
Operating activities generated $5.4 million in cash; investing activities used $0.1 million, while financing activities used $4.9 million. Cash declined $1.1 million during the year, including a $1.6 million unfavorable foreign-exchange effect. The company reported $8.7 million of available borrowing capacity and compliance with credit-facility financial covenants at year-end. Its credit agreement matures March 29, 2018, with $11.4 million of debt scheduled to mature in 2018. Substantially all company assets secure the debt, and the facility contains financial and other restrictive covenants. The company said current cash, operating cash generation and debt capacity were expected to support operations, potential acquisitions and capital expenditures for at least the next 12 months and beyond; this is a forward-looking assessment, not formal earnings guidance.
Changes, unusual items and outlook
- Revenue from non-U.S. operations was approximately 38% of total revenue, down from 40% in 2015; management cited currency effects and softer European funding. Direct end-user sales represented approximately 64% of revenue, with distributor sales at 36%.
- AHN, a liquid-handling products business with $2.1 million of 2016 revenue, was sold in October 2016 for approximately $1.7 million gross proceeds ($1.4 million net of cash on hand). The sale resulted in a $0.7 million impairment charge and a $1.2 million loss.
- Other unusual 2016 costs included approximately $1.7 million of forensic investigation costs. The filing does not provide a detailed description of the investigation in the supplied text.
- Management cited facility consolidation and operational efficiency as priorities, alongside commercial excellence, product development and strategic acquisitions. It expects continued investment in research and development but provided no specific revenue or earnings targets.
- Key risks include dependence on research budgets and government funding, international and foreign-exchange exposure, competition and technological change, acquisition integration, and debt maturity/refinancing. The company also highlighted Brexit-related uncertainty and the risk that facility consolidation savings may not meet expectations.
- Goodwill and intangible assets were $56.7 million, or 53% of total assets. Management reported no impairment of goodwill or indefinite-lived intangibles at year-end, but recorded the AHN long-lived asset impairment.
- Management and the auditor identified material weaknesses in internal control over financial reporting, involving inventory costing and reserves at MCS and current and deferred income-tax controls. The auditor issued an adverse opinion on internal control effectiveness; the financial-statement audit opinion was unqualified. Remediation was ongoing, with completion not assured.
Most important facts for investors to verify
- Whether revenue trends stabilize and whether the stated causes of the 2016 decline, including currency and research-funding softness, persist.
- Whether improved gross margin converts into operating profitability, and how recurring results compare after AHN-sale, impairment and forensic-investigation costs.
- Progress in remediating the inventory and tax-control material weaknesses, and whether future filings disclose effective controls without further misstatements.
- The company’s ability to refinance, repay or extend the credit facility before its March 2018 maturity while meeting covenants and maintaining adequate liquidity.
- Cash availability: $4.5 million of the $5.6 million year-end cash balance was held by foreign subsidiaries and was not available for U.S. operations without repatriation.
- The basis for management’s liquidity outlook and the impact of ongoing pension obligations, lease commitments and any future acquisition spending.